119 related articles for article (PubMed ID: 17461715)
1. Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib.
de Lima Lopes G; Rocha Lima CM
Pharmacotherapy; 2007 May; 27(5):775-7. PubMed ID: 17461715
[TBL] [Abstract][Full Text] [Related]
2. Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib.
Gomez-Abuin G; Karam AA; Mezzadri NA; Bas CA
Clin Genitourin Cancer; 2009 Jan; 7(1):62-3. PubMed ID: 19213671
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
5. [Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma].
Choi SW; Lee JM; Kim DG; Noh MH
Korean J Gastroenterol; 2020 Feb; 75(2):103-107. PubMed ID: 32098465
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic application of sunitinib malate in the management of gastrointestinal stromal tumors.
MacIntyre J
Clin J Oncol Nurs; 2007 Apr; 11(2):237-41. PubMed ID: 17573273
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes.
Dong Z; Gao J; Gong J; Li J; Li Y; Shen L; Li J
Future Oncol; 2017 Oct; 13(23):2035-2043. PubMed ID: 28685593
[TBL] [Abstract][Full Text] [Related]
8. Successful desensitization protocol for hypersensitivity reaction caused by sunitinib in a patient with a gastrointestinal stromal tumor.
Bar-Sela G; Kedem E; Hadad S; Pollack S; Haim N; Atrash F; Shahar E
Jpn J Clin Oncol; 2010 Feb; 40(2):163-5. PubMed ID: 19797416
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.
Michels J; Lassau N; Gross-Goupil M; Massard C; Mejean A; Escudier B
Invest New Drugs; 2010 Oct; 28(5):690-3. PubMed ID: 19547920
[TBL] [Abstract][Full Text] [Related]
10. Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature.
Gallucci G; Tartarone A; Tocchetti CG; Bochicchio AM; Coccaro M; Capobianco A; Maurea N; Improta G; Zupa A; Aieta M
Future Oncol; 2013 Jan; 9(1):127-33. PubMed ID: 23252570
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
Turan N; Benekli M; Ozturk SC; Inal S; Memis L; Guz G; Cetin B; Buyukberber S
Ann Pharmacother; 2012 Oct; 46(10):e27. PubMed ID: 23032654
[TBL] [Abstract][Full Text] [Related]
12. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences.
Chow H; Jung A; Talbott J; Lin AM; Daud AI; Coakley FV
J Comput Assist Tomogr; 2011; 35(1):86-90. PubMed ID: 21245693
[TBL] [Abstract][Full Text] [Related]
13. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
14. Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor.
Jarkowski A; Hare R; Francescutti V; Wilkinson N; Khushalani N
Anticancer Res; 2011 Oct; 31(10):3429-32. PubMed ID: 21965757
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
16. [Drug Interaction between Sutent (sunitinib) and Bi-spirogyl (spiramycin-metronidazol): risk of toxicity].
Trabelsi S; Boussen H; Gaïes E; Salouage I; El Aïdli S; Daghfous R; Loueslati MH; Lakhal M; Belkahia C
Therapie; 2008; 63(6):475-6. PubMed ID: 19374036
[No Abstract] [Full Text] [Related]
17. The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.
Seandel M; Shia J; Linkov I; Maki RG; Antonescu CR; Dupont J
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6203-4. PubMed ID: 17062698
[No Abstract] [Full Text] [Related]
18. Cardiotoxicity associated with sunitinib.
Hariharan S; Lowry S
Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
[No Abstract] [Full Text] [Related]
19. Sunitinib-induced pseudoporphyria.
Sanz-Motilva V; Martorell-Calatayud A; Llombart B; Requena C; Serra-Guillén C; Nagore E; Guillén C; Traves V; Sanmartín O
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1848-50. PubMed ID: 24813651
[No Abstract] [Full Text] [Related]
20. Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report.
Watanabe K; Otsu S; Morinaga R; Kawano S; Hirashima Y; Sakashita H; Shirao K
BMC Gastroenterol; 2010 Nov; 10():128. PubMed ID: 21040530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
